442 related articles for article (PubMed ID: 15830313)
1. [Recurrent strongyloidiasis as an indicator of HTLV-1 infection].
Richter J; Schwarz U; Duwe S; Ellerbrok H; Poggensee G; Pauli G
Dtsch Med Wochenschr; 2005 Apr; 130(16):1007-10. PubMed ID: 15830313
[TBL] [Abstract][Full Text] [Related]
2. Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection.
Jeyamani R; Joseph AJ; Chacko A
Trop Gastroenterol; 2007; 28(4):176-7. PubMed ID: 18416349
[TBL] [Abstract][Full Text] [Related]
3. Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection.
Hirata T; Uchima N; Kishimoto K; Zaha O; Kinjo N; Hokama A; Sakugawa H; Kinjo F; Fujita J
Am J Trop Med Hyg; 2006 Feb; 74(2):246-9. PubMed ID: 16474078
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis.
Carvalho EM; Da Fonseca Porto A
Parasite Immunol; 2004; 26(11-12):487-97. PubMed ID: 15771684
[TBL] [Abstract][Full Text] [Related]
5. Case Report:
De Souza JN; Soares BNRR; Goes LL; Lima CS; Barreto NMPV; Jacobina BS; Gonçalves N; Teixeira MCA; Galvão-Castro B; Grassi MFR; Soares NM
Am J Trop Med Hyg; 2018 Dec; 99(6):1583-1586. PubMed ID: 30277207
[No Abstract] [Full Text] [Related]
6. Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases.
Peters L; McCarthy AE; Faught C
Int J Infect Dis; 2009 Nov; 13(6):e501-3. PubMed ID: 19501008
[TBL] [Abstract][Full Text] [Related]
7. Atypical clinical presentation of strongyloidiasis in a patient co-infected with human T cell lymphotrophic virus type I.
Porto MA; Alcântara LM; Leal M; Castro N; Carvalho EM
Am J Trop Med Hyg; 2005 Feb; 72(2):124-5. PubMed ID: 15741545
[TBL] [Abstract][Full Text] [Related]
8. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.
Ashida C; Kinoshita K; Nozaki Y; Funauchi M
BMC Infect Dis; 2020 Jul; 20(1):470. PubMed ID: 32615937
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous manifestation of disseminated strongyloidiasis in a patient coinfected with HTLV-I.
Arch EL; Schaefer JT; Dahiya A
Dermatol Online J; 2008 Dec; 14(12):6. PubMed ID: 19265619
[TBL] [Abstract][Full Text] [Related]
10. Strongyloides stercoralis: a cause of morbidity and mortality for indigenous people in Central Australia.
Einsiedel L; Fernandes L
Intern Med J; 2008 Sep; 38(9):697-703. PubMed ID: 19143887
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous manifestations of Strongyloides stercoralis hyperinfection in an HIV-seropositive patient.
Martin SJ; Cohen PR; MacFarlane DF; Grossman ME
Skinmed; 2011; 9(3):199-202. PubMed ID: 21675505
[TBL] [Abstract][Full Text] [Related]
12. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis.
Pornsuriyasak P; Niticharoenpong K; Sakapibunnan A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):531-4. PubMed ID: 15689061
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of ivermectin in the treatment of children parasitized by Strongyloides stercoralis].
Ordóñez LE; Angulo ES
Biomedica; 2004 Mar; 24(1):33-41. PubMed ID: 15239599
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa, Japan.
Toma H; Sato Y; Shiroma Y; Kobayashi J; Shimabukuro I; Takara M
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):147-51. PubMed ID: 11023084
[TBL] [Abstract][Full Text] [Related]
15.
Hashiba Y; Umekita K; Minami H; Kawano A; Nagayasu E; Maruyama H; Hidaka T; Okayama A
Mod Rheumatol Case Rep; 2021 Jan; 5(1):16-21. PubMed ID: 32772699
[TBL] [Abstract][Full Text] [Related]
16. [An overview of Strongyloides stercoralis and its infections].
Ardiç N
Mikrobiyol Bul; 2009 Jan; 43(1):169-77. PubMed ID: 19334396
[TBL] [Abstract][Full Text] [Related]
17. Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis.
Satoh M; Toma H; Sugahara K; Etoh K; Shiroma Y; Kiyuna S; Takara M; Matsuoka M; Yamaguchi K; Nakada K; Fujita K; Kojima S; Hori E; Tanaka Y; Kamihira S; Sato Y; Watanabe T
Oncogene; 2002 Apr; 21(16):2466-75. PubMed ID: 11971181
[TBL] [Abstract][Full Text] [Related]
18. Gastric strongyloidiasis and infection by the human T cell lymphotropic virus type 1 (HTLV-1).
Lambertucci JR; Leão FC; Barbosa AJ
Rev Soc Bras Med Trop; 2003; 36(4):541-2. PubMed ID: 12937738
[No Abstract] [Full Text] [Related]
19. [Combined infection with HTLV-1 and Strongyloides stercoralis].
Pays JF
Bull Soc Pathol Exot; 2011 Aug; 104(3):188-99. PubMed ID: 21800110
[TBL] [Abstract][Full Text] [Related]
20. [Human T-lymphotropic virus 1 (HTLV-1), strongyloidiasis and scabies. Infections and associations to considerate].
Freites A
Invest Clin; 2008 Dec; 49(4):455-6. PubMed ID: 19245164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
